What is the rationale behind the €3.59 million equity-settled share-based payments in H1 2025 given recent performance?

The €3.59 million in equity-settled share-based payments for InflaRx N.V. (IFRX) in H1 2025, as noted in their financial statements, typically reflects non-cash compensation expenses related to employee and executive incentives. These payments are a common component of compensation packages in biotechnology and pharmaceutical companies, aiming to align the interests of employees with shareholders by granting stock options, restricted stock units (RSUs), or other equity awards. The rationale often extends beyond immediate financial performance to long-term strategic goals, such as drug development milestones, regulatory approvals, or sustained growth, which may not always be directly reflected in short-term financial results.

While the immediate financial performance might be a concern, share-based compensation is often tied to multi-year vesting schedules and performance targets that look beyond a single reporting period. For instance, the company might be incentivizing continued progress on its clinical pipeline, such as the development of vilobelimab, or aiming to retain key talent in a competitive industry. These expenses are typically recognized over the vesting period of the awards, meaning the €3.59 million recognized in H1 2025 could relate to awards granted in prior periods or new grants with a future-oriented vesting schedule. Understanding the specific terms of these equity awards, such as vesting conditions and performance hurdles, would provide a clearer picture of the company's intended rationale.